Terms: = Uterine cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
2 results:
1. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
Wu Y; Huang J; Ivan C; Sun Y; Ma S; Mangala LS; Fellman BM; Urbauer DL; Jennings NB; Ram P; Coleman RL; Hu W; Sood AK
Gynecol Oncol; 2021 Oct; 163(1):181-190. PubMed ID: 34391578
[TBL] [Abstract] [Full Text] [Related]
2. Primary squamous cell carcinoma of the endometrium: clinicopathologic and molecular characteristics.
Bures N; Nelson G; Duan Q; Magliocco A; Demetrick D; Duggan MA
Int J Gynecol Pathol; 2013 Nov; 32(6):566-75. PubMed ID: 24071873
[TBL] [Abstract] [Full Text] [Related]
